Table 6.

Summary of Total Opioid Consumption^a by Time Interval

	All Subjects
Interval	Meloxicam IV (n = 537)b	Placebo (n = 183)	P Valuec	P Valued
0‐24 h	17.9 ± 22.86	23.3 ± 27.90	.0025	<.0001
24‐48 he	8.7 ± 19.20	11.3 ± 21.82	.0846	.0015
48‐72 hf	4.1 ± 16.59	6.2 ± 21.83	.2725	.1530
0‐48 h	26.3 ± 37.73	34.3 ± 44.08	.0060	<.0001
0‐72 h	28.4 ± 45.49	37.4 ± 55.31	.0126	<.0001
During treatment	29.8 ± 58.02	39.0 ± 68.08	.0531	<.0001

	Orthopedic Surgery
	Meloxicam IV (n = 282)b	Placebo (n = 96)	P Valuec	P Valued
0‐24 h	22.1 ± 22.75	31.1 ± 30.87	.0032	.0006
24‐48 he	11.7 ± 18.67	15.7 ± 23.92	.0362	.0067
48‐72 hf	5.3 ± 11.13	8.6 ± 22.80	.2178	.2768
0‐48 h	33.5 ± 37.05	46.3 ± 46.51	.0032	<.0001
0‐72 h	35.9 ± 40.86	50.0 ± 55.59	.0037	<.0001
During treatment	36.8 ± 42.69	50.3 ± 47.7	.0081	<.0001

	Other Surgery
	Meloxicam IV (n = 255)	Placebo (n = 87)	P Valuec	P Valued
0‐24 h	13.3 ± 22.14	14.6 ± 21.23	.4704	.0409
24‐48 he	5.3 ± 19.25	6.4 ± 18.21	.7216	.0600
48‐72 hf	3.1 ± 20.09	4.3 ± 21.07	.3507	.2830
0‐48 h	18.4 ± 36.96	20.9 ± 37.13	.5078	.0081
0‐72 h	20.2 ± 48.88	23.5 ± 51.84	.5308	.0069
During treatment	22.1 ± 70.53	26.5 ± 77.95	.5734	.0072

IV indicates intravenous.

^aIntravenous morphine equivalent dose (mg, mean ± SD).

^bExcluded 1 subject who had erroneous data that could not be confirmed.

^c P value from analysis of covariance for treatment group difference.

^d P value from Cochran‐Mantel‐Haenszel analysis on rank controlling center.

^en = 519, 275, and 244, respectively, for meloxicam IV and n = 178, 93, and 85, respectively, for placebo, in all subjects, orthopedic surgery, and other surgery.

^fn = 274, 126, and 148, respectively, for meloxicam IV and n = 93, 41, and 52, respectively, for placebo, in all subjects, orthopedic surgery, and other surgery.